[1] |
JIANG Wenshuo, YANG Li.
Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
|
[2] |
ZHANG Lei, LYU Jian, XIE Yanming.
Efficacy and safety of Houpupaiqi Mixture in the treatment of postoperative lieus: a Meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 799-806.
|
[3] |
CHENG Fengjingming, LYU Jian, XIE Yanming.
Efficacy and safety of compound salvia miltiorrhiza spray/aerosol for angina pectoris due to coronary artery disease: a Meta analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 536-543.
|
[4] |
FAN Xiucong, DONG Xiaohui, CHEN Danxia, BAO Siwei, MA Yabin.
Pharmaceutical care of a patient with Clostridium difficile infection and urinary tract infection during pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 579-582.
|
[5] |
SU Xinxin, LYU Jian, XIE Yanming.
Efficacy and safety of Toutongning capsules in the treatment of chronic headache: a Meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 433-440.
|
[6] |
LI Meng, LI Rongrong, LIU Chenghai.
Clinic diagnosis and treatment of herb-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 127-131.
|
[7] |
ZHAO Huanhuan, SONG Jiawei, LIU Jinguang, HUANG Minghui.
One case of nephrotic syndrome caused by rabies vaccine in a 5-year-old child
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1303-1305.
|
[8] |
WANG Tao, ZHENG Mingjie, LIU Hongliang, WANG Qing, SHEN Chuanyong.
Current applications of artificial intelligence in pharmacovigilance in the USA and implications
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1129-1133.
|
[9] |
YU Min, LI Xin.
Immunerelated adverse events and risk factors of carrelizumab in 528 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1134-1140.
|
[10] |
YUAN Xiaolong, WAN Qihua, TAO Donghong, QI Hao, WANG Aixia.
Pharmaceutical care of a severely poisoned patient with methotrexate tablets
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 924-928.
|
[11] |
ZHU Jinying, ZHOU Sufeng, WANG Lu, XU Mingzhe, SHAO Feng.
Advances in pediatric drug for central sedation based on pharmacokinetic/pharmacodynamic modeling and simulation
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 721-727.
|
[12] |
WEI Xianni, XU Huiyi, HUANG Yuhong, XIE Genying.
Influencing factors and treatment of drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 665-669.
|
[13] |
LI Yu, FAN Huihui, FENG Xiaojun, ZHANG Yonghuang, CHEN Qin, WANG Yunhong, CHEN Chuantao, ZHANG Lei, SHI Tianlu.
Association between ABCB1 C3435T polymorphisms and methotrexate-induced toxicity in childhood acute lymphoblastic leukemia: Meta analysis
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 421-425.
|
[14] |
CHEN Shuang, ZHENG Shufen, ZHANG Shuyao, ZHONG Shilong.
Adverse reactions of tumor immunotherapy drugs—PD-1/PD-L1 inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1107-1112.
|
[15] |
SU Xinxin, LI Lixun, WANG Zhifei, XIE Yanming, WANG Qi.
Real-world study on Xiyanping injection combined in the treatment of childhood pneumonia
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 47-51.
|